| 摘要 |
The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity. |
| 申请人 |
FIVE PRIME THERAPEUTICS, INC.;LIN, JUNYU;KOTHAKOTA, SRINIVAS;WU, GE;DOBERSTEIN, STEPHEN;BRENNAN, THOMAS;MASUOKA, LORIANNE;QIN, MINMIN;MARSHALL, SHANNON;WANG, YAN;HOLLENBAUGH, DIANE;WILLIAMS, LEWIS, T. |
发明人 |
LIN, JUNYU;KOTHAKOTA, SRINIVAS;WU, GE;DOBERSTEIN, STEPHEN;BRENNAN, THOMAS;MASUOKA, LORIANNE;QIN, MINMIN;MARSHALL, SHANNON;WANG, YAN;HOLLENBAUGH, DIANE;WILLIAMS, LEWIS, T. |
